Immutep Announces US$5.2 Million Financing Led by U.S. Specialist Healthcare Investor, Altium Capital
December 19, 2018 07:00 ET
|
Immutep Limited
Extends the Company’s cash runway into mid-2020, during which time Immutep is expected to report meaningful clinical data SYDNEY, Australia, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:...
New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented at the 4th Annual ICI Europe Summit
November 27, 2018 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), announces new data from its ongoing TACTI-mel Phase I clinical trial is...
Immutep Presents Positive New Data from Ongoing TACTI-mel Study at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
November 12, 2018 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
Operational Update
November 01, 2018 08:00 ET
|
Immutep Limited
Highlights Site selection process advancing for planned TACTI-002 Phase II trial which will include recruitment of up to 110 patientsAIPAC Phase IIb recruitment reaches 155 patients or more than 68%...
Immutep Announces Data Presentations at Upcoming Industry Conferences
October 24, 2018 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
Immutep Announces Presentations at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
October 02, 2018 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference
September 26, 2018 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
Immutep Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA, Darmstadt, Germany, and Pfizer
September 24, 2018 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) is pleased to announce that it has entered into a clinical trial...
Progress Towards Clinical Development of IMP761 – a LAG-3 Agonist Antibody
September 03, 2018 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Sept. 03, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”, the “Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep Receives A$1.9 Million Research and Development Related Tax Rebate from French Government
August 21, 2018 04:44 ET
|
Immutep Limited
SYDNEY, Australia, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...